Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026. Corporate Highlights Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini Announced that it has selected a full-service co